NEW YORK : The S&P 500 and the Nasdaq ended higher, while the Dow closed lower after a choppy trading session on Thursday, as ...

W.G. Nunn Elementary School recently announced its 2nd Nine Weeks Honor Roll: 1st Grade Honor Roll w/Distinction: De’Monei Brantley, Keith Brown, Adelynn Brown-Murray, Malaysia Carter, Teyanna Denson, ...

LabConnect, a leading provider of central lab services and functional service provider solutions, is proud to announce the ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...

Terence Flynn, Morgan Stanley, inquired about Zepbound payer dynamics and access. Patrik Jonsson explained that Medicare coverage related to obstructive sleep apnea (OSA) is anticipated in the second ...

Eli Lilly and Co. (LLY) on Thursday reported fourth-quarter earnings of $4.41 billion. The Indianapolis-based company said it had profit of $4.88 per share. Earnings, adjusted for one-time gains and ...

Eli Lilly (LLY) is set to announce Q4 earnings results, with analysts expecting positive growth driven by key drugs and new product launches.

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...

Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. In a fresh appearance on CNBC's Squawk on the Street, Jim Cramer cautioned ...